tetano
Editor, Senior Moderator
Cureus
. 2022 Jan 7;14(1):e21009.
doi: 10.7759/cureus.21009. eCollection 2022 Jan.
COVID-19 mRNA Vaccine-Associated Myocarditis
Htin Kyaw[SUP] 1 [/SUP], Shehanaz Shajahan[SUP] 1 [/SUP], Amit Gulati[SUP] 1 [/SUP], Shwe Synn[SUP] 2 [/SUP], Sakshi Khurana[SUP] 3 [/SUP], Nijas Nazar[SUP] 4 [/SUP], Suvash Shrestha[SUP] 5 [/SUP], Joshua Kerstein[SUP] 5 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) has been reported to cause cardiovascular complications including myocarditis, pericardial effusion, pericarditis, and arrhythmias. With the introduction of the vaccine, there have been reports of myocarditis possibly associated with the mRNA COVID-19 vaccine. We report a case of cardiac involvement following the second dose of Pfizer-BioNTech COVID-19 vaccine in a young male. A healthy 24-year-old male presented to the emergency department with complaints of non-radiating mid-sternal chest pain and pressure. He noticed his symptoms started six hours after he received the second dose of Pfizer COVID vaccine. Laboratory tests revealed elevated cardiac troponin I-CtNI levels. Computed tomography angiography of the chest did not show evidence of pulmonary embolism. Given his presentation of acute chest pain associated with elevated troponin levels, a coronary angiogram was performed which revealed normal coronary arteries. He was subsequently treated for acute peri-myocarditis with colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), and beta-blockers for tachycardia and the prevention of arrhythmia. Although rare, clinicians should be aware of the risk for myocarditis and pericarditis, which should be considered in individuals presenting with chest pain within a week after vaccination, especially in the younger population. Although the long-term risk in these patients is uncertain, early diagnosis and treatment are key to minimizing complications.
Keywords: covid pericarditis; covid-19; myocardial injury; myocarditis; vaccine associated myocarditis.
. 2022 Jan 7;14(1):e21009.
doi: 10.7759/cureus.21009. eCollection 2022 Jan.
COVID-19 mRNA Vaccine-Associated Myocarditis
Htin Kyaw[SUP] 1 [/SUP], Shehanaz Shajahan[SUP] 1 [/SUP], Amit Gulati[SUP] 1 [/SUP], Shwe Synn[SUP] 2 [/SUP], Sakshi Khurana[SUP] 3 [/SUP], Nijas Nazar[SUP] 4 [/SUP], Suvash Shrestha[SUP] 5 [/SUP], Joshua Kerstein[SUP] 5 [/SUP]
Affiliations
- PMID: 35154981
- PMCID: PMC8820479
- DOI: 10.7759/cureus.21009
Abstract
Coronavirus disease 2019 (COVID-19) has been reported to cause cardiovascular complications including myocarditis, pericardial effusion, pericarditis, and arrhythmias. With the introduction of the vaccine, there have been reports of myocarditis possibly associated with the mRNA COVID-19 vaccine. We report a case of cardiac involvement following the second dose of Pfizer-BioNTech COVID-19 vaccine in a young male. A healthy 24-year-old male presented to the emergency department with complaints of non-radiating mid-sternal chest pain and pressure. He noticed his symptoms started six hours after he received the second dose of Pfizer COVID vaccine. Laboratory tests revealed elevated cardiac troponin I-CtNI levels. Computed tomography angiography of the chest did not show evidence of pulmonary embolism. Given his presentation of acute chest pain associated with elevated troponin levels, a coronary angiogram was performed which revealed normal coronary arteries. He was subsequently treated for acute peri-myocarditis with colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), and beta-blockers for tachycardia and the prevention of arrhythmia. Although rare, clinicians should be aware of the risk for myocarditis and pericarditis, which should be considered in individuals presenting with chest pain within a week after vaccination, especially in the younger population. Although the long-term risk in these patients is uncertain, early diagnosis and treatment are key to minimizing complications.
Keywords: covid pericarditis; covid-19; myocardial injury; myocarditis; vaccine associated myocarditis.